PanGen Biotech Inc. (KOSDAQ:222110)
South Korea flag South Korea · Delayed Price · Currency is KRW
5,170.00
+150.00 (2.99%)
At close: Aug 11, 2026

PanGen Biotech Revenue

PanGen Biotech had revenue of 3.73B KRW in the quarter ending March 31, 2026, with 8.43% growth. This brings the company's revenue in the last twelve months to 13.71B, down -6.37% year-over-year. In the year 2025, PanGen Biotech had annual revenue of 13.42B, down -8.56%.

Revenue (ttm)
13.71B
Revenue Growth
-6.37%
P/S Ratio
5.10
Revenue / Employee
n/a
Employees
n/a
Market Cap
69.87B

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 202513.42B-1.26B-8.56%
Dec 31, 202414.67B7.36B100.58%
Dec 31, 20237.32B814.47M12.53%
Dec 31, 20226.50B-1.43B-18.08%
Dec 31, 20217.94B1.74B28.18%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Related Stocks

Company NameRevenue
CTCBIO128.76B
KoBioLabs71.21B
J2KBIO36.82B
Naturalendo Tech21.69B
BIO-FD&C18.85B
QuadMedicine9.78B
EyeGene4.02B
NovMetaPharma1.30B
Revenue Rankings